Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients
| Autor: | Alyssa R Bartels, Natalie K Ketchen, Sachinkumar B. Singh, Brittany A. Wright, Leah N Rasmussen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Vitamin medicine.medical_specialty Indoles Pyrrolidines Malabsorption Adolescent Cystic Fibrosis Pyridines Population Cystic Fibrosis Transmembrane Conductance Regulator Quinolones Aminophenols Gastroenterology Cystic fibrosis Ivacaftor Young Adult chemistry.chemical_compound Internal medicine medicine Vitamin D and neurology Humans Benzodioxoles Vitamin D Child Chloride Channel Agonists education education.field_of_study biology business.industry Vitamins medicine.disease Mucus Cystic fibrosis transmembrane conductance regulator chemistry Mutation Pediatrics Perinatology and Child Health biology.protein Pyrazoles Female business medicine.drug |
| Zdroj: | Pediatric Pulmonology. 57:655-657 |
| ISSN: | 1099-0496 8755-6863 |
| DOI: | 10.1002/ppul.25781 |
| Popis: | BACKGROUND Cystic fibrosis (CF) is a multisystem disorder that results in the buildup of mucus in various organs. Ninety percent of CF patients are classified as pancreatic insufficient, leading to malabsorption of nutrients and fat-soluble vitamins without the assistance of exogenous pancreatic enzymes. This study was designed to determine if serum 25-hydroxyvitamin D concentrations were impacted by initiation of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). METHODS Serum 25-hydroxyvitamin D concentrations were measured prior to and 1 year post-ELX/TEZ/IVA initiation. A Wilcoxon signed-rank test was used to compare values. RESULTS Seventy-six patients were included in the final analysis. The average age of our population was 25.8 years (SD = 13.2 years) with a majority being male, homozygous F508del, pancreatic insufficient, and not modulator-naive. The median increase of serum vitamin D concentration after initiating ELX/TEZ/IVA was 5 ng/mL ((IQR) = -4, 13; p = 0.0035). CONCLUSIONS We suggest that ELX/TEZ/IVA may improve fat-soluble vitamin absorption, specifically serum 25-hydroxyvitamin D. These results may lead to adjustments in vitamin supplementation in patients receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text